New drug cocktail targets Hard-to-Treat endometrial cancer

NCT ID NCT07318324

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This early-phase study tests a combination of three drugs (avutometinib, defactinib, and everolimus) in people with recurrent endometrial cancer that has specific genetic changes in the RAS pathway. The main goal is to find a safe dose and understand side effects. About 31 participants will take part in this study at M.D. Anderson Cancer Center.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AVUTOMETINIB are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm RASopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AVUTOMETINIB ENDOMETRIAL PHASE IB RAS PATHWAY

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.